b483502d-4e7f-46ff-b0f2-e35c51047efb
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 59
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- COAGULATION+0.340
- TNFA_SIGNALING_VIA_NFKB+0.330
- NOTCH_SIGNALING+0.300
- TGF_BETA_SIGNALING+0.260
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.230
- WNT_BETA_CATENIN_SIGNALING+0.220
- P53_PATHWAY+0.190
- BILE_ACID_METABOLISM+0.180
- ESTROGEN_RESPONSE_EARLY+0.180
- ANGIOGENESIS+0.140
Top 10 suppressed
- E2F_TARGETS-0.660
- G2M_CHECKPOINT-0.580
- MYC_TARGETS_V1-0.500
- MTORC1_SIGNALING-0.460
- DNA_REPAIR-0.370
- MYC_TARGETS_V2-0.360
- CHOLESTEROL_HOMEOSTASIS-0.350
- UNFOLDED_PROTEIN_RESPONSE-0.350
- GLYCOLYSIS-0.280
- PI3K_AKT_MTOR_SIGNALING-0.270
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1313091 | — | A | 0.858 |
| 2 | SRR1313130 | — | A | 0.857 |
| 3 | TCGA-MS-A51U-01A-31R-A266-07 | — | A | 0.855 |
| 4 | TCGA-B6-A0RP-01A-21R-A084-07 | — | B | 0.852 |
| 5 | TCGA-A2-A0EW-01A-21R-A115-07 | — | A | 0.848 |
| 6 | TCGA-BH-A0DP-01A-21R-A056-07 | — | A | 0.847 |
| 7 | TCGA-A7-A5ZW-01A-12R-A29R-07 | — | A | 0.838 |
| 8 | TCGA-55-8207-01A-11R-2241-07 | — | cohortA1 | 0.836 |
| 9 | C3N-02193 | — | cohortA1 | 0.827 |
| 10 | SRR8613732 | — | A | 0.826 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| COAGULATION | 0.340 | Binimetinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.330 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.300 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.260 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.230 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.220 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.190 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.180 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.180 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.140 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.140 | Inavolisib | — uncovered |
| PEROXISOME | 0.130 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.120 | Inavolisib | — uncovered |
| APOPTOSIS | 0.110 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.110 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.090 | Temsirolimus | — uncovered |
| FATTY_ACID_METABOLISM | 0.090 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.090 | Temsirolimus | — uncovered |
| ALLOGRAFT_REJECTION | 0.080 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.060 | Inavolisib | — uncovered |